$395.2M in CY2024 Part D spend31K claims · 5K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Ixazomib used for?
NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Is there a generic for Ixazomib?
No. Ixazomib is brand-only with no generic equivalents currently in market.
How much does my plan pay for Ixazomib?
NADAC pricing data not currently available for this drug.
Is Ixazomib on the FDA shortage list?
No. Ixazomib is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.